Merck KGaA presents clinical trial data for Erbitux
DARMSTADT, Germany A biotech drug originally approved to treat neck cancer also may treat non-small cell lung cancer, according to study data presented at a conference in San Francisco on Aug. 2.
Merck KGaA announced the presentation of data from an analysis of four mid-stage and late-stage clinical trials of Erbitux (cetuximab) at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer.
The analysis, which included data on more than 2,000 patients, found that when added to first-line chemotherapy, Erbitux increased overall survival in patients with NSCLC.
Merck KGaA markets Erbitux in Europe, while Bristol-Myers Squibb and Eli Lilly & Co. subsidiary ImClone Systems market it in the United States. Merck KGaA is a separate company from United States-based Merck & Co. and operates in the United States under the name EMD.
Craig C. Phillips elected VP, general manager of the oncology business unit at Cephalon
FRAZER, Pa. Cephalon announced Craig C. Phillips was elected VP and general manager of the oncology business unit.
Phillips will be responsible for managing all aspects of the U.S. oncology business including sales, marketing and medical affairs.
“Since joining Cephalon two years ago, Craig has clearly demonstrated an ability to exceed expectations and bring value to our organization through his leadership,” said Robert Roche, EVP of worldwide pharmaceutical operations. “I am confident that Craig’s leadership and vision will support the dynamic growth of the Cephalon oncology business and allow us to continue to bring medicines that matter to the healthcare professionals and patients battling cancer.”
Spartan fights economy with jump in net sales
GRAND RAPIDS, Mich. Supermarket operator Spartan Stores had a $9.3 million jump in consolidated net sales during first quarter of its fiscal year 2010, the company announced in an earnings release this week.
That and a 9.4% increase in EBITDA stemmed mostly from Spartan’s acquisition of VG’s Food and Pharmacy stores, the company said. First-quarter operating earnings increased moderately, to $15.1 million compared with first quarter fiscal year 2009.
“We are pleased to report steady operating profits despite the prolonged economic challenges and the incremental costs associated with this year’s business and operational initiatives,” Spartan president and CEO Dennis Eidson said in a statement. “As anticipated, comparable store sales at our retail supermarkets declined during the quarter due to economic uncertainty, which is causing changes in consumer purchase behavior, such as a shift to lower-priced private label products, and price deflation in certain high-volume product categories.”